Victhom Human Bionics Inc V.VHB

RE: RE: RE: Why so quiet?

[modulex]

I am forwarding an article (although from 2006) by Montreal newspaper writer Robert Gibbens who normally follows up on investors concerns about public companies who are, so to speak, in a standstill situation, that keep a low profile about their future. Mr. Gibbens can be reached at [e-mail] should you want to submit that Victhom must reveal to its shareholders where it intends to bring the company forward. As you pointed it out, the TSX requirements dictates that a company must be a functioning business and actually "do" business and not just become a shall company. I assume that Victhom has already reported to the TSX the current status of the company and that nothing abnormal requires the delisting of the shares at this point. In any event, should the shares become ultimately delisted at some point, shareholders would be entitled to a distribution. My feeling is that the company is working out either an acquisition or a merger. That explains why its share price is relatively flat at
.04. There will definitely be something unfolding by the fall of 2012. It seems that the company is no longer reporting financial results as the last time it occured was for Q3 2011, released in November 2011. We are 5 months later and nothing is disclosed on WWW.VICTHOM.COM website. I am trying to find out who are the major shareholders of the company in order to find out what they have to say about the company at this stage. It would not be inappropriate for shareholders to unite and make a request to the company to clearly states where its future relies upon? You can try to reach the company at:

For more information: Normand Rivard

President & CEO

Victhom Human Bionics Inc.

Tel.: [phone]

Fax: [phone]

[e-mail]

www.victhom.com

They will reply to you.

ROBERT GIBBENS, The Gazette
Published: Thursday, July 27, 2006

Quebec City's Victhom Human Bionics Inc., inventor of the bionic leg that former Quebec premier Lucien Bouchard has tested, reaches a pivotal point in its seven-year existence Jan. 1.

That's when Iceland's Ossur Co., an international prosthetics group that is Victhom's financial and marketing partner, begins selling the commercial version of the bionic leg in affiliated clinics in North America and Europe, said Benoit Huet, who took over as CEO from Benoit Cote in May.

These sales will give Victhom its first real product revenue stream. With other products based on the same technology in its pipeline, Victhom can begin moving toward break even and the next stage of its development, he said.

The PowerKnee, as the patented device is also known, replicates the lost limb's function so an amputee can tackle stairs and uneven surfaces.

Sensors in the prosthetic foot feed information on terrain to microprocessors while the other foot's sensors instruct the knee's battery-fed motor and artificial limb to move in real time.

Founder-inventor Stephane Bedard's ambition is to let amputees have a normal human gait while using a minimum of their own energy.

Existing artificial limbs run into problems with stairs and broken surfaces, experts say.

Early in 2004, Bouchard joined a group of about 15 people to test the bionic leg during the pre-commercial development stage.

"It is a genuine solution to the problems associated with wearing a conventional prosthesis," he said.

The former premier, who lost his left leg in a bout with the "flesh-eating disease" (necrotizing fasciitis) in 1994, still attends training sessions for the bionic leg at a Montreal clinic when he has the time, Bedard says.

"The stock market has been tough on us, but expectations got out of line," said Montrealer Huet, 48, a former Novartis Pharma executive in Germany and recently CEO of Montreal researcher Enobia Pharma.

"It took longer than expected to complete the pre-commercialization of the bionic leg, but the marketing is near."

A decade ago, Bedard injured a knee in a mountain-bike accident and met amputees in rehab. Then a mechanical engineering student at Universite Laval, he decided he could do better than existing "artificial" limbs. His one-man start-up has grown into a 91-employee publicly traded research firm with a world reputation. He remains executive vice-president and COO.

In the last quarter of 2005, Victhom posted revenue of $1.5 million, up from $396,000 a year earlier, with rising "milestone" payments received from Ossur and collaboration with a U.S. medical device firm. It reduced its loss by 35 per cent to $1.6 million. Huet's next quarterly report is due Aug. 11 and there won't be any surprises. Analysts see the better trend continuing.

Victhom went public early in 2003 at $1 a share to raise $3 million and the financing and marketing pact with Ossur followed in May 2003. Since 2004, it has raised about $32 million, mostly by private placement, to fund its research and now has $15 million in cash. It holds 32 patents covering its bionic devices, with more pending.




ROBERT GIBBENS, The Gazette
Published: Thursday, July 27, 2006

Huet said Victhom has a three-year "window" before competitors catch up with its bionic technology. "Some big companies are already buying up small research firms specializing in the field," he said. "But with Ossur, we're going to exploit that window."

Victhom will produce the first 50 bionic legs and then Ossur takes over manufacturing as well as distribution worldwide. Ossur plans to begin at the high end of the market, selling the bionic leg at around $100,000, including training. That's twice the price of existing conventional products. Gradually, the price will come down, Huet said.

Victhom is developing other products using the same platform, including a bionic brace for both arms and legs ready for the market in the shorter term.

Another is Neurostep, designed to treat gait disorders stemming from strokes, multiple sclerosis, spinal cord injuries, cerebral palsy, brain injuries and polio. It will seek Health Canada approval for human trials before yearend.

Victhom is also working hard in neuroelectronics, applying its sensing know-how to help people suffering from asthma, diabetes, obesity, urinary disorders and chronic pain. The 2004 acquisition of Vancouver's Neurostream Technologies gave it an implantable "pacemaker" device that measures and stimulates nerve activity.

Victhom's shares closed yesterday at 64 cents, down 4 cents.

[e-mail]
© The Gazette (Montreal) 2006